FierceBiotech 9. Jan. 2026 Quanterix nabs Illumina’s CCO as new leader, but Leerink warns of ‘significant lift’ needed for turnaround
FierceBiotech 9. Jan. 2026 Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
FierceBiotech 9. Jan. 2026 Illumina hires former NHGRI Director Eric Green as new chief medical officer
FierceBiotech 9. Jan. 2026 Roche returns to MediLink with promise of $570M near-term payments for another ADC
FierceBiotech 9. Jan. 2026 Ollin eyes phase 3 after bispecific tops Vabysmo in early-stage trial, clearing more retinal disease faster
FierceBiotech 8. Jan. 2026 Longtime Charles River leader Jim Foster to retire, with COO set to take the helm
FierceBiotech 8. Jan. 2026 Lexeo Therapeutics, J&J team up to test heart pump technology for cardiac gene therapy delivery
FierceBiotech 8. Jan. 2026 Startup Spiro Medical snares $67M in series A funding for asthma treatment
FierceBiotech 8. Jan. 2026 Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution
FierceBiotech 8. Jan. 2026 Diagonal moves forward with $125M series B round, plots first-in-human study this year